Condition: Hepatocellular Carcinoma Resectable · Sponsor: Zhujiang Hospital
This study will conduct a prospective cohort study to verify the predictive value of ctDNA-MRD longitudinal monitoring model in predicting postoperative recurrence, verify whether ctDNA-MRD longitudinal monitoring model can indicate recurrence earlier than imaging examination, and explore the feasibility of guiding adjuvant therapy after curative treatment based on this model.
This description comes directly from the study's public registry record.
Mingxin Pan, Prof. · +8618928918216 · pmxwxy@sohu.com
Cheng Zhang · 13242781120 · 754167410@qq.com
Always discuss trial participation with your own doctor first.
| The Sixth Affiliated Hospital of South China University of Technology | Foshan, Guangdong, China | Recruiting |
| Zhujiang Hospital of Southern Medical University | Guangzhou, Guangdong, China | Recruiting |
| Affiliated Cancer Hospital and Institute of Guangzhou Medical University | Guangzhou, Guangdong, China | Recruiting |
| Guangdong Provincial Hospital of Traditional Chinese Medicine | Guangzhou, Guangdong, China | Recruiting |
| Shunde Hospital of Southern Medical University | Guangzhou, Guangdong, China | Recruiting |
| Sun Yat-sen University Cancer Center | Guangzhou, Guangdong, China | Recruiting |
| Yuebei People's Hospital | Shaoguan, Guangdong, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06157060